ARCA biopharma, Inc. (ABIO): Price and Financial Metrics


ARCA biopharma, Inc. (ABIO): $2.42

0.01 (+0.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ABIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ABIO Stock Price Chart Interactive Chart >

Price chart for ABIO

ABIO Price/Volume Stats

Current price $2.42 52-week high $3.90
Prev. close $2.41 52-week low $1.71
Day low $2.40 Volume 35,000
Day high $2.44 Avg. volume 143,555
50-day MA $2.35 Dividend yield N/A
200-day MA $2.42 Market Cap 34.87M

ARCA biopharma, Inc. (ABIO) Company Bio


ARCA biopharma, Inc. operates as a biopharmaceutical company applying a precision medicine approach to developing and commercializing genetically targeted therapies for cardiovascular diseases. Its lead product candidate, Gencaro (bucindolol hydrochloride) is pharmacogenetically-targeted beta-adrenergic receptor antagonist, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). The company also engages in the development of AB171, a thiol-substituted isosorbide mononitrate for the treatment of HF and peripheral arterial disease. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.


ABIO Latest News Stream


Event/Time News Detail
Loading, please wait...

ABIO Latest Social Stream


Loading social stream, please wait...

View Full ABIO Social Stream

Latest ABIO News From Around the Web

Below are the latest news stories about ARCA biopharma Inc that investors may wish to consider to help them evaluate ABIO as an investment opportunity.

Data on Gencaro Impact on Prevention of Bradycardia Published in Heart Rhythm O2

Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Clinically important bradycardia is common in heart failure (HF) patients with persistent or paroxysmal atrial fibrillation (AF)In a Phase 2B clinical trial, the prevalence of clinically important bradycardia was statistically significantly lower for GencaroTM compared to metoprolol WESTMINSTER, Colo., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision med

Yahoo | January 4, 2022

Financial Survey: ARCA biopharma (ABIO) & Its Peers

ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related businesses based on the strength of its earnings, institutional ownership, dividends, profitability, risk, valuation and analyst recommendations. Risk & Volatility ARCA biopharma has []

Transcript Daily | December 13, 2021

Head-To-Head Contrast: ARCA biopharma (ABIO) and Its Peers

ARCA biopharma (NASDAQ: ABIO) is one of 38 publicly-traded companies in the Diagnostic substances industry, but how does it weigh in compared to its rivals? We will compare ARCA biopharma to related companies based on the strength of its earnings, risk, profitability, valuation, dividends, institutional ownership and analyst recommendations. Risk and Volatility ARCA biopharma has []

Dakota Financial News | December 11, 2021

Contrasting ARCA biopharma (ABIO) & Its Peers

ARCA biopharma (NASDAQ: ABIO) is one of 38 public companies in the Diagnostic substances industry, but how does it compare to its peers? We will compare ARCA biopharma to related businesses based on the strength of its risk, dividends, institutional ownership, valuation, profitability, analyst recommendations and earnings. Analyst Recommendations This is a breakdown of current []

Dakota Financial News | December 10, 2021

Indices - Reviewing ARCA biopharma & Its Peers

ARCA biopharma is one of 38 public companies in the Diagnostic substances industry, but how does it contrast to its peers? We will compare ARCA biopharma to related

Business Mag | December 9, 2021

Read More 'ABIO' Stories Here

ABIO Price Returns

1-mo 2.11%
3-mo 19.21%
6-mo 2.33%
1-year -30.66%
3-year -60.65%
5-year -94.51%
YTD 12.56%
2021 -46.38%
2020 -29.78%
2019 -3.86%
2018 -75.56%
2017 -52.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4181 seconds.